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Abstract
BACKGROUND: There has been an overall improvement in survival rates for persons with 
cancer over the past 35 years. However, these gains are less prevalent among adolescents with 
cancer aged 15 to 19 years, which may be due to lower clinical trial enrollment among adolescents 
with cancer.
METHODS: We conducted a literature review to assess current research regarding clinical trial 
enrollment and subsequent outcomes among adolescents with cancer. The search included 
English-language publications that reported original data from January 1985 to October 2011.
RESULTS: The search identified 539 records. Of these 539 records, there were 30 relevant 
original research articles. Multiple studies reported that adolescents with cancer are enrolled in 
clinical trials at lower rates compared with younger children and older adults. Treatment setting, 
physician type, and institution type may all be factors in the low enrollment rate among 
adolescents. Few data focused solely on adolescents, with many studies combining adolescents 
with young adults. The number of available studies related to this topic was limited, with 
significant variability in study design, methods, and outcomes.
CONCLUSIONS: This literature review suggests that adolescents with cancer are not treated at 
optimal settings and are enrolled in clinical trials at low rates. This may lead to inferior treatment 
and poor subsequent medical and psychosocial outcomes. The scarcity in data further validates the 
need for additional research focusing on this population.
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Over the past 35 years, the number of cancer survivors in the United States has grown from 
<3 million to nearly 12 million.1 Although there have been improvements in cancer survival, 
morbidity, and quality of life in the overall population of US cancer survivors, these gains 
are less prevalent among adolescents aged 15 to 19 years diagnosed with cancer.2–4 This 
situation is especially true when compared with younger children aged 0 to 14 years and 
older adults,2–4 for whom improved outcomes are correlated to enrollment in clinical trials.5
Adolescents with cancer are enrolled in clinical trials at much lower rates in the United 
States compared with younger children and older adults.5–7 One reason adolescents are 
enrolled in clinical trials at low rates is because of referral patterns.8–10 Unlike younger 
children or older adults, adolescents with cancer may be referred by pediatricians to either 
pediatric or adult oncologists.11 Most adolescents are referred to adult oncology centers, and 
the referral of adolescents to pediatric oncology centers diminishes with age.11–13 Adult 
cancer centers have lower rates of clinical trial enrollment and less access to clinical trials 
for adolescents compared with pediatric cancer centers. Additionally, there is evidence that 
adolescents diagnosed with certain types of cancer who are treated on pediatric protocols 
have better outcomes compared with those on adult protocols.14–17 To address these and 
other issues related to clinical trial enrollment and health outcomes for adolescent 
survivorship, we examined the scientific literature regarding this topic. We performed a 
literature review to assess current research regarding treatment setting, clinical trial 
enrollment, and subsequent outcomes among adolescents with cancer.
METHODS
The literature review focused on treatment setting, enrollment in clinical trials, and 
subsequent medical and psychosocial outcomes among adolescents with cancer. To examine 
psychosocial outcomes, we examined adolescents who participated in randomized controlled 
trials targeting behavioral change and emotional symptoms related to cancer trajectory. With 
the use of the OVID, EBSCOhost, Medline, and Embase search platforms, we performed a 
keyword search of 5 databases: Medline, Embase, the Psychological Abstracts database 
(PsychINFO), Cochrane Library, and the Cumulative Index of Nursing and Allied Health 
Literature database. We reviewed reference lists of eligible articles found through the initial 
search to identify additional articles. We also identified additional articles not abstracted in 
the initial search in a cursory review from researchers and practitioners in the fields of 
oncology and health psychology. Figure 1 shows an example of a search syntax we used. We 
limited results to peer-reviewed original research studies from the United States, the United 
Kingdom, Australia, and Canada published in English between January 1, 1985, and 
October 31, 2011.
A 2-phase classification procedure was used to determine relevance. In phase I, a primary 
reviewer assessed all titles and abstracts and classified them as either potentially relevant, 
relevant, or not relevant. In phase II, the primary reviewer reviewed the full text of all 
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potentially relevant articles and classified them as either relevant or not relevant. A quality 
assurance procedure with 3 reviewers was used to verify the accuracy of relevance 
classifications. A first reviewer read a 25% random sample of articles and classified them as 
potentially relevant, relevant, or not relevant. A second reviewer repeated this process 
independently. Results from the 2 reviewers were sent to a third reviewer who identified and 
reconciled any discordance in classification.
RESULTS
The combined database and reference list searches resulted in 66 relevant articles (Fig 2). Of 
these 66 articles, 36 were review articles or commentaries and 30 were original research 
articles. Of the 30 original research articles, there were 4 randomized controlled trials, 2 
prospective cross-sectional studies, and 24 retrospective cross-sectional studies (Table 1). 
Although there was an emphasis on cancer types most commonly found in the adolescent 
population, the majority of articles examined all cancer types. Among all articles, there was 
variation in the definition of the adolescent and adolescent and young adult (AYA) 
population; age ranges were as low as 13 years for adolescents and up to 40 years for young 
adults. We present an overview of the relevant articles by the following topic areas: 
treatment setting, clinical trial enrollment, and subsequent outcomes.
Treatment Setting
Several studies focused primarily on the setting in which adolescents with cancer were 
treated. One study in Ohio found that of 169 adolescent patients aged 15 to 19 years, 47% 
were treated at pediatric institutions, 25% were treated at adult academic centers, and 29% 
were treated at community hospitals.18 Treatment at pediatric centers decreased with 
increasing age. However, cancer type was found to be an important diagnostic factor 
independent of age: malignancies traditionally regarded as “pediatric,” such as acute 
lymphoblastic leukemia, central nervous system tumors, and osteosarcomas, were treated 
more often at pediatric hospitals regardless of age, whereas malignancies traditionally 
regarded as “adult,” such as melanoma and germ cell tumors, were more often treated at 
adult institutions regardless of age.18 Another study in Canada found that ~30% of 
adolescents aged 15 to 19 years were treated at a pediatric institution.19 Consistent with the 
study from Ohio, the likelihood of treatment at a pediatric institution decreased with 
increasing age, and adolescents treated at adult institutions were more likely to have a 
diagnosis of carcinoma or germ cell tumor and less likely to have lymphoma.19 Another 
study found that only 14% of adolescents aged 16 to 19 years were treated at a pediatric 
institution.20
Clinical Trial Enrollment
A number of identified studies assessed clinical trial enrollment among adolescents with 
cancer. The range of adolescent patients enrolled in clinical trials ranged from 5% to 34%. A 
study of Children’s Oncology Group enrollment data showed that only 21% of patients aged 
15 to 19 years of age were enrolled in clinical trials.5 The Children’s Oncology Group 
accounted for >97% of all clinical trial participants <20 years of age, whereas adult 
cooperative groups collectively accounted for <3% of clinical trials for adolescents in the 
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15- to 19-year range.21 A National Cancer Institute Patterns of Care study showed that 34% 
of adolescents aged 15 to 19 years were enrolled in a clinical trials.22 The study showed that 
older patients and those treated by adult oncologists were less likely to be enrolled into 
clinical trials.22 A decreasing rate of clinical trial enrollment with increasing age was also 
seen in the Los Angeles County Cancer Surveillance Program.23 Adolescents aged 15 to 19 
years, compared with children aged 14 and younger, were less commonly diagnosed at a 
Children’s Oncology Group institution and were also enrolled in a clinical trial at lower 
rates.23 In addition to lower clinical trial enrollment rates among adolescents, there were 
also fewer therapeutic trials available for this age group.23 A comparison of clinical trial 
enrollment between adolescent and young adult oncology patients aged 15 to 22 years 
treated at affiliated adult and pediatric centers revealed that clinical trial enrollment was 
higher with treatment at a pediatric center. Of 91 cases with new cancer diagnoses treated at 
the pediatric center, 24 (26%) were enrolled, whereas only 5 of 121 (4%) cases with new 
cancer diagnoses treated at the adult center were enrolled in a clinical trial24 A study in 
Australia showed that adolescents aged 10 to 19 years were more likely to be enrolled in a 
clinical trial if treated at a pediatric institution rather than at an adult institution (38% vs 
3%).20 Even if adolescents are seen at a pediatric institution, appropriate clinical trials may 
not be available. In a study in 640 patients with newly diagnosed cancer at a pediatric 
institution, 38% of patients under the age of 15 years were enrolled in a clinical trial and 
27% of patients aged 15 to 22 years were enrolled in a clinical trial25 More than half of the 
older patients were not enrolled because a trial was not available.25 Clinical trial enrollment 
may be affected not only by differences in pediatric and adult institutions but by differences 
in academic compared with community institutions. Because most clinical trials are 
primarily conducted at academic institutions, most accrual into these trials is from academic 
centers. By reaching out to community oncologists and practices, physicians and researchers 
in academic settings may expand access to clinical trials.18 Cooperative group protocols that 
could be implemented practically at community hospitals and outpatient offices could 
increase patient accrual.18
There is also evidence that clinical trial enrollment is improved when adolescent patients are 
seen at a dedicated AYA oncology program.26 In the 3 years before the establishment of an 
AYA program at the University of Pittsburgh, clinical trial enrollment at the adult center was 
4%. In the 4 years after the creation of the AYA program, clinical trial enrollment at the 
pediatric center and adult center increased to 33%.26 Thus, the development of AYA 
programs may be a strategy to increase clinical trial enrollment for adolescent patients with 
cancer.26 Another potential strategy to increase clinical trial enrollment is expanding 
national clinical trials accessibility to patients treated at both pediatric and medical oncology 
tertiary care centers through collaboration between pediatric and adult oncologists.24–26 This 
collaboration could be facilitated through improved communication between pediatric and 
adult oncologists, such as the establishment of an AYA cancer resource network that 
provides current information about currently available clinical trials.20,22
Survival
Several studies reported on survival trends among adolescents with cancer.27–37 A number 
of studies showed that increasing age was a poor prognostic factor for certain cancers, 
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including acute myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt’s and Burkitt-Iike 
lymphoma, and rhabdomyosarcoma.29–32 Two studies reported that adolescents with acute 
lymphoblastic leukemia were shown to have superior outcomes when treated on pediatric 
protocols compared with adult protocols.27,28 Despite limitations in the comparison of 
clinical trials due to differences in methodology, comparative studies indicate that 
adolescents with cancer may have a survival advantage when treated on pediatric protocols 
compared with adult protocols.27,28 However, this finding may not hold true for all patients, 
cancers, and therapies. Ultimately, improved survival may be best achieved by risk-directed 
selection of therapies based on the biology and response to therapy.27 The age limits for 
recruitment into clinical trials may need to be reconsidered.27,28
Psychosocial Outcomes
Several studies have identified that adolescent cancer survivors and their families may 
struggle with posttraumatic stress disorder, depression, and other clinical emotional and 
behavioral concerns as a result of their cancer diagnosis, treatment, and long-term trajectory.
38
 However, the onset, frequency, and duration of adverse emotional or behavioral symptoms 
and diagnosed psychosocial disorders among adolescent cancer survivors are vastly 
underexplored. Psychosocial interventions and their effect on psychosocial outcomes of 
adolescent cancer survivors have been examined in randomized controlled trials.39 Two 
randomized controlled trials showed that an integrated cognitive-behavioral and family 
therapy approach as well as a telephone-delivered coping skills training intervention may be 
effective components in the reduction in posttraumatic stress symptoms and other symptoms 
among adolescent cancer survivors.40–42 Efforts to decrease posttraumatic stress symptoms 
are especially important in this population because stress may increase risk behaviors such 
as physical inactivity, smoking, and nonadherence to sun protection among adolescent 
cancer survivors.43 One study examined the effect of a multicomponent educational 
intervention to decrease risk behaviors and health-protective behaviors among adolescent 
cancer survivors44 Results indicated that age and gender may have a strong influence on the 
impact of interventions targeting health behaviors in this population, and future trials should 
consider more factors including an improved understanding of patient-clinician interactions, 
patient motivations, and more specific outcome measures.44
DISCUSSION
This literature review suggests that adolescents with cancer are not treated at optimal 
settings and are enrolled in clinical trials at low rates. This situation may lead to inferior 
treatment and poor subsequent medical and psychosocial outcomes. Barriers that prevent 
adolescents from enrolling in clinical trials include the treatment setting, treating physician, 
and institution type. Adolescents with cancer are often referred to nonpediatric centers and 
community hospitals. Access to clinical trials is more limited for adolescents in these 
settings compared with pediatric tertiary care institutions, thereby reducing the possibility of 
clinical trial enrollment for a majority of adolescents with cancer.
Increasing referral to pediatric centers, when appropriate, is needed to increase enrollment of 
adolescents in clinical trials. Because it may be more appropriate for adolescents with 
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certain types of cancer, such as melanoma and germ cell tumors, to be treated at adult 
institutions for medical reasons, it is also important to increase enrollment for adolescents 
with cancer who are seen in adult and community settings. This increase may be achieved 
through collaboration between pediatric and adult institutions and oncologists. There is also 
a need for unified clinical trial protocols for adolescents that can be followed by both 
pediatric and adult oncologists in national cooperative groups. Increased collaboration may 
also be facilitated through dedicated AYA oncology programs, which have been shown to 
increase clinical trials enrollment for both adolescents and young adults.
The number of available studies related to this topic was limited. The identified studies had 
significant variability in study design, methods, populations, and outcomes. Therefore, 
conclusions based on these studies may not be generalizable to all populations. The lack of a 
standardized age category may also lead to misclassification and bias among the studies 
reviewed.
The limited number and scope of articles identified through this literature review is reflective 
of the small but emerging view of adolescents with cancer as a distinct and unique entity. 
Results from this literature review indicate that few data focused solely on adolescents are 
available, with many studies combining adolescents with young adults. This scarcity in data 
further validates the need for additional research focusing on this population. The experience 
and needs of adolescent patients with cancer are different from those of other age groups in 
many respects. Continued focus on the biology of AYA tumors, therapies to improve 
survival and decrease toxicity, and the long-term impacts of cancer treatment is needed. 
Increased attention is needed on initial engagement with the health care system after a 
cancer diagnosis, including referral and choosing optimal treatment settings and physicians. 
As the cancer survivor population continues to increase, it is of public health importance that 
adolescents are not excluded from improvements seen in other age groups and receive the 
highest standard of care.
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FIGURE 1. 
Sample search syntax for Medline, Embase, PsychINFO, and Cochrane databases.
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FIGURE 2. 
Flowchart of article screening, assessment, and inclusion.
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TABLE 1
Studies on Patterns of Referral, Clinical Trial Enrollment, and Subsequent Outcomes Among Adolescents 
With Cancer
First Author Year Sample Size Age of 
Study 
Population
Study Design Type of Cancer Primary Outcome
Alderfer39 2009 144 11–19 y Prospective, cross-sectional All Family functioning
Baider45 1989 8 15–25 y Prospective, cross-sectional All Psychological distress
Bleyer5 1997 29 859 0–20 y Retrospective, cross-sectional All Clinical trial enrollment
Burkhardt30 2011 378 15–18 y Retrospective, cross-sectional Non-Hodgkin’s lymphoma Survival
Cairo29 2003 470 0–21 y Retrospective, cross-sectional Burkitt’s lymphoma Survival
Cox44 2005 272 12–18 y Randomized controlled trial All Behavior change
Creutzig31 2007 1181 0–30 y Retrospective, cross-sectional Acute myeloid leukemia Survival
Downs-Canner24 2009 91 15–22 y Retrospective, cross-sectional All Clinical trial enrollment
Hill46 2007 77 7–19 y Retrospective, cross-sectional Colorectal
Clinical and pathologic 
features
Joshi32 2004 2343 0–21 y Retrospective, cross-sectional Rhabdomyosarcoma Survival
Judge Santacroce41 2009 21 15–25 y Randomized controlled trial All Coping skills
Kazak40 2004 150 11–19 y Randomized controlled trial All Posttraumatic stress symptoms
Klein-Geltink19 2005 204 15–19 y Retrospective, cross-sectional All Provider type
Krailo23 1993 2788 0–19 y Retrospective, cross-sectional All Clinical trial enrollment
Millot34 2011 44 10 mo–17 y Retrospective, cross-sectional Chronic myelogenous leukemia Survival
Mitchell20 2004 576 10–24 y Retrospective, cross-sectional All Clinical trial enrollment
Moreno33 2009 16 14–24 y Retrospective, cross-sectional Ependymoma Survival
Pao47 2006 347 1–21 y Retrospective, cross-sectional All Psychotropic medication use
Parsons22 2011 1358 15–39 y Retrospective, cross-sectional All Factors associated with 
clinical trial enrollment
Pinkerton36 2010 11 915 0–29 y Retrospective, cross-sectional Hematologic malignancies Survival
Polishchuk35 2011 39 ≥10 y Retrospective, cross-sectional Neuroblastoma Survival
Portteus48 2006 216 — Retrospective, cross-sectional All Antidepressant medication use
Ramanujachar27 2007 128 15–17 y Retrospective, cross-sectional Acute lymphoblastic leukemia Provider type
Ramanujachar28 2006 48 15–21 y Retrospective, cross-sectional Acute lymphoblastic leukemia Provider type
Shaw25 2007 640 0–22 y Retrospective, cross-sectional All Clinical trial enrollment
Shaw26 2010 57 15–22 y Retrospective, cross-sectional All Clinical trial enrollment
Silverman37 2010 1457 0–18 y Retrospective, cross-sectional Acute lymphoblastic leukemia Survival
Sultan49
2010
159 4–20 y Retrospective, cross-sectional Colorectal Clinical and pathologic 
features
Tercyak43 2006 75 11–21 y Randomized controlled trial All Behavioral risk factors
Yeager18 2006 169 15–19 y Retrospective, cross-sectional All Provider type
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